MARKET

VNDA

VNDA

Vanda Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.75
+0.13
+1.35%
After Hours: 9.75 0 0.00% 16:01 05/25 EDT
OPEN
9.64
PREV CLOSE
9.62
HIGH
9.84
LOW
9.56
VOLUME
297.53K
TURNOVER
0
52 WEEK HIGH
21.86
52 WEEK LOW
9.24
MARKET CAP
550.77M
P/E (TTM)
30.96
1D
5D
1M
3M
1Y
5Y
Vanda Pharmaceuticals Announces Presentations at DDW 2022
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2022, to be held in San Diego, CA and online from May 21-24, 2022.
PR Newswire · 6d ago
Most likely large-cap and small-cap merger candidates -BofA
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based
Seekingalpha · 05/15 15:42
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -1,000% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 23:15
Vanda Pharmaceuticals Q1 EPS $(0.11) Misses $(0.01) Estimate, Sales $60.20M Beat $58.00M Estimate
Vanda Pharmaceuticals (NASDAQ:VNDA) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.01) by 1000 percent. This is a 173.33 percent decrease over earnings of $0.15 per
Benzinga · 05/05 21:38
Vanda Pharmaceuticals GAAP EPS of -$0.11 misses by $0.10, revenue of $60.19M beats by $2.19M
Vanda Pharmaceuticals press release (NASDAQ:VNDA): Q1 GAAP EPS of -$0.11 misses by $0.10. Revenue of $60.19M (-4.0% Y/Y) beats by $2.19M.
Seekingalpha · 05/05 20:26
-- Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $60.2M, vs. Street Est of $58M
MT Newswires · 05/05 16:22
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
Earnings Outlook For Vanda Pharmaceuticals
Vanda Pharmaceuticals (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vanda Pharmaceuticals will report an earnings per share (EPS...
Benzinga · 05/04 21:24
More
No Data
Learn about the latest financial forecast of VNDA. Analyze the recent business situations of Vanda Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VNDA stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
High10.00
Average10.00
Low10.00
Current 9.75
EPS
Actual
Estimate
-0.040.020.090.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 264
Institutional Holdings: 70.69M
% Owned: 125.13%
Shares Outstanding: 56.49M
TypeInstitutionsShares
Increased
61
4.62M
New
21
823.71K
Decreased
72
2.09M
Sold Out
30
1.33M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mihael Polymeropoulos
Chief Financial Officer/Senior Vice President/Treasurer/IR Contact Officer
Kevin Moran
Senior Vice President/Chief Marketing Officer
Joakim Wijkstrom
Senior Vice President/General Counsel/Secretary
Timothy Williams
Senior Vice President
Gunther Birznieks
Lead Director/Independent Director
H. Thomas Watkins
Independent Director
Phaedra Chrousos
Independent Director
Richard Dugan
Independent Director
Stephen Mitchell
Independent Director
Anne Ward
No Data
No Data
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.

Webull offers kinds of Vanda Pharmaceuticals Inc. stock information, including NASDAQ:VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.